Technical Data
E0255-55C
EBAG9 (Estrogen Receptor-binding Fragment-associated Gene 9 Protein, EB9, Cancer-associated Surface Antigen RCAS1, PDAF, Receptor-binding Cancer Antigen Expressed on SiSo Cells, RCAS1)
Description:
Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
Daudi lysate

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to C-KEAQRLMKKEQN, from the C-terminus of the protein sequence according to NP_004206.1.
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in Tris saline, 0.02% sodium azide, pH7.3, 0.5% BSA.
Specificity:
Recognizes human EBAG9. Species sequence homology: canine, mouse, rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Ruder C, Reimer T, Delgado-Martinez I, Hermosilla R, Engelsberg A, Nehring R, Dorken B, Rehm A. EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin. Mol Biol Cell. 2005 Mar;16(3):1245-57. Epub 2005 Jan 5. PMID: 15635093.